XenoPort in the Storm: GSK Split Ends Horizant Squabble
By Randy Osborne
Friday, November 9, 2012
It wasn't the first time that a deal by GlaxoSmithKline plc left Wall Street unsatisfied and ultimately fizzled, but the severing of XenoPort's tie with the pharma giant leaves the biotech in fairly good shape: full rights to Horizant (gabapentin enacarbil) and $20 million in new equity money.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.